PPT-Switch to DRV/r + RPV

PROBE Study PROBE Study switch to DRVr RPV Design Age 18 years HIV No previous resistance to study drugs HIV1 RNA lt 50 cml 6 months On stable 6 months PIr 2 NRTI TDFFTC or ABC3TC. Effects of Atazanavir, . Raltegravir. . or Darunavir with FTC/Tenofovir . on Biomarkers . of Systemic Inflammation, Macrophage and T-Cell Activation: . ACTG A5260s . T. . Kelesidis. , . T.T.T. . Tran, . vs. PI/r . monotherapy. Study PIVOT. Study MOBIDIP. LPV/r monotherapy (N = 82). Design. Randomisation. 1: 1. Open-label. Objective. Primary endpoint. : failure rate at W96 by ITT, defined as 1) a confirmed HIV . Study GS-US-292-0119. E/C/F/TAF + DRV 800 mg QD. N = 89. N = 46. Baseline regimen. Design. Randomisation*. 2: 1. Open-label. Objective. Primary Endpoint: proportion with treatment success (HIV RNA < 50 c/mL) . May 2018. BUILDER Overview. 2. BUILDER SMS. 3. A part of a web-based software application Sustainment Management System (SMS). Developed by Construction Engineering Research Laboratory (CERL), Engineer Research and Development Center, US Army Corps of Engineers. 1 Queen Mary University, London, United Kingdom; 2 EPIMED GmbH, Berlin, Germany; 3 Hospital Universitario Fundación Jiménez Díaz , Madrid, Spain; 4 Central Institute of Epidemiology, Moscow, Russian Federation; 1 University of Nebraska Medical Center, Omaha, NE, United States; 2 University of Guadalajara, Guadalajara, Mexico; 3 Broward Health Medical Center, Fort Lauderdale, FL, United States; 4 Fatebenefratelli Sacco Hospital, Milan, Italy; G-103 Ckbeceopap (Pubkop( CO>E) (Last updated December 24, 2019, last reviewed December 24, 2019)Carcinogenicity Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infectio Matter. Sokratis . Trifinopoulos. PLANCK. . 2019. Granada, . 04 June . 2019. [T.]. . 1904.12940 . Outline. Background and Motivation. RPV and DM . interactions under the . U. (2). 2. . flavour . symmetry . Every 2 Months for HIV Maintenance. . ATLAS-2M. IM Cabotegravir and IM . Rilpivirine. Every 2 Months for HIV Maintenance. ATLAS-2M Study. : Design. Source: Overton ET, et al. Lancet. 2020:396:1994-2005.. Virally Suppressed Adults. www.hivguidelines.org. MAY 2023. NYSDOH AIDS Institute Clinical Guidelines Program. Purpose of This Guideline. Weigh the risks and benefits of switching from an oral to an injectable ART regimen. S. VIDARD . (EDF / SEPTEN. ) - N. JARDIN . (EDF / UNIE. ) - A.M. DONORE . (EDF / R&D. ). 4. th. . PLiM. . conference. Lyon, . october. 2017. Summary. EDF 3-loop RPV life management beyond 40 years of operation . Study GS-366-1216. Switch from TDF to TAF, each with RPV and FTC. Study GS-366-1216: Design. Source: . Orkin. C et al. Lancet HIV. 2017;4:e195-e204.. *. NOTE. :. of 632 participants randomized, 2 were never treated (630 individuals treated). DRV/r 800/100 + 3TC 300 QD. N = 126. N = 123. DRV/r + ABC/3TC or TDF/FTC QD. Design. Randomisation*. 1: 1. Open-label. Objective. Non inferiority of DRV/r + 3TC at W48: % HIV RNA < 50 c/mL by intention to treat-exposed, snapshot analysis (lower margin of the 2-sided 95% CI for the difference = - 12%, 80% power). /r and . Metabolic . Parameters . METABOLIK. DRV/r . versus . ATV/r . and Metabolic Parameters . METABOLIK. : . Study Design . Source. : . Aberg. JA, et al. AIDS Res Hum Retroviruses. . 2012;28:. 1184-95..